ArticleInternational journal of clinical oncology2024
Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy.
Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- CT-derived myosteatosis as a predictor of postoperative outcomes in esophagogastric cancer surgery: a systematic review.Frontiers in medicine · 2026Pooled it
- Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis.Abdominal radiology (New York) · 2025Pooled it
- Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.PloS one · 2024Pooled it
- Article
- Association of Underweight, Sarcopenia, and Cancer Cachexia with Survival Outcomes in Hypopharyngeal Cancer Radiotherapy.Cancers · 2026Article
- Sarcopenia as a Marker of Immunometabolic Vulnerability in Pancreatic Ductal Adenocarcinoma.Cancers · 2026Review
- Impact of C3 Vertebra-Based Sarcopenia and Clinical Factors on Postoperative Complications in Oral Cancer Patients.Cancers · 2026Article
- A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.Frontiers in nutrition · 2026Article
- Preoperative nutritional status and sarcopenia are associated with disease-free survival in patients with resected pancreatic neuroendocrine tumors.Frontiers in oncology · 2026Article
- Integrated CT-based assessment of muscle and adiposity for risk stratification in advanced pancreatobiliary cancer.Frontiers in nutrition · 2026Article
- The albumin-myosteatosis gauge predicts the response to neoadjuvant chemotherapy for locally advanced gastric cancer.Surgery today · 2025Article
- Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib.Current oncology (Toronto, Ont.) · 2025Article
- The relationship between sarcopenia, nutritional status, physical function, and quality of life in elderly cancer patients: a path analysis.BMC geriatrics · 2025Article
- Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.Immunotherapy · 2025Article
- Postoperative Changes in Body Composition Predict Long-Term Prognosis in Patients with Gastric Cancer.Cancers · 2025Article
- Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis.iScience · 2024Article
- Strength in quality: Myosteatosis as a predictor of survival in advanced hepatocellular carcinoma.United European gastroenterology journal · 2024Article
- Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia and myosteatosis have been associated with a poor prognosis for several cancers. The albumin-myosteatosis gauge (AMG) is a novel integrated measure proposed to assess myosteatosis along with serum albumin level as a surrogate of systemic inflammation and malnutrition. The aim of this study was to investigate the prognostic value of AMG in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
methodsPatients with advanced PDAC treated with chemotherapy between 2013 and 2022 were evaluated. Skeletal muscle radiodensity (SMD) and skeletal muscle index (SMI) were calculated using computed tomography at the level of the L3 vertebra. The AMG was defined as albumin x SMD and expressed as an arbitrary unit (AU). Patients were first categorized by sex-specific quartiles and then dichotomized at the sex-specific median value of the AMG.
resultsA total of 196 patients were included. The median age (interquartile range) was 62 (54-67), and 128 (65.3%) were male. With regard to AMG, 142.86 and 114.15 AU were identified as cutoff values for males and females, respectively. In multivariable analyses, lower AMG values (G1-G2 vs. G3-G4) (HR: 1.61, 95% CI 1.17-2.21, p = 0.003), higher ECOG performance score (> 0 vs. 0) (HR: 1.51, 95% CI 1.10-2.06, p = 0.009) and metastatic disease (vs. locally advanced) (HR: 1.88, 95% CI 1.27-2.79, p = 0.001) were associated with OS.
conclusionThe study findings suggest the prognostic value of AMG in patients with advanced PDAC undergoing first-line chemotherapy. Further studies are warranted to validate these findings and assess potential predictive role of AMG in guiding treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.